OliX PharmaceuticalsInc (226950) - Net Assets
Based on the latest financial reports, OliX PharmaceuticalsInc (226950) has net assets worth ₩150.08 Billion KRW (≈ $101.71 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩195.37 Billion ≈ $132.40 Million USD) and total liabilities (₩45.29 Billion ≈ $30.69 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check OliX PharmaceuticalsInc tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩150.08 Billion |
| % of Total Assets | 76.82% |
| Annual Growth Rate | 31.74% |
| 5-Year Change | 710.31% |
| 10-Year Change | N/A |
| Growth Volatility | 243.68 |
OliX PharmaceuticalsInc - Net Assets Trend (2016–2025)
This chart illustrates how OliX PharmaceuticalsInc's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of OliX PharmaceuticalsInc to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for OliX PharmaceuticalsInc (2016–2025)
The table below shows the annual net assets of OliX PharmaceuticalsInc from 2016 to 2025. For live valuation and market cap data, see OliX PharmaceuticalsInc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩150.08 Billion ≈ $101.71 Million |
+740.83% |
| 2024-12-31 | ₩17.85 Billion ≈ $12.10 Million |
-64.54% |
| 2023-12-31 | ₩50.34 Billion ≈ $34.11 Million |
-23.63% |
| 2022-12-31 | ₩65.91 Billion ≈ $44.66 Million |
+255.85% |
| 2021-12-31 | ₩18.52 Billion ≈ $12.55 Million |
-59.10% |
| 2020-12-31 | ₩45.29 Billion ≈ $30.69 Million |
+8.34% |
| 2019-12-31 | ₩41.80 Billion ≈ $28.33 Million |
-23.92% |
| 2018-12-31 | ₩54.94 Billion ≈ $37.23 Million |
+194.16% |
| 2017-12-31 | ₩18.68 Billion ≈ $12.66 Million |
+48.73% |
| 2016-12-31 | ₩12.56 Billion ≈ $8.51 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to OliX PharmaceuticalsInc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18443418112000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩340.97 Billion | 228.25% |
| Total Equity | ₩149.38 Billion | 100.00% |
OliX PharmaceuticalsInc Competitors by Market Cap
The table below lists competitors of OliX PharmaceuticalsInc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Anhui Kouzi Distillery Co Ltd
SHG:603589
|
$1.76 Billion |
|
Nexa Resources SA
NYSE:NEXA
|
$1.76 Billion |
|
Zhewen Interactive Group Co Ltd
SHG:600986
|
$1.76 Billion |
|
Hunan Nanling Industrial Explosive Materials Co Ltd
SHE:002096
|
$1.76 Billion |
|
Voyager Technologies, Inc.
NYSE:VOYG
|
$1.76 Billion |
|
Triputra Agro Persada Tbk PT
JK:TAPG
|
$1.76 Billion |
|
Topscore Fashion
SHG:603608
|
$1.76 Billion |
|
Dynavax Technologies Corporation
NASDAQ:DVAX
|
$1.76 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in OliX PharmaceuticalsInc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 17,848,889,860 to 149,379,304,620, a change of 131,530,414,760 (736.9%).
- Net loss of 15,742,651,450 reduced equity.
- New share issuances of 122,513,002,540 increased equity.
- Other factors increased equity by 24,760,063,670.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-15.74 Billion | -10.54% |
| Share Issuances | ₩122.51 Billion | +82.01% |
| Other Changes | ₩24.76 Billion | +16.58% |
| Total Change | ₩- | 736.91% |
Book Value vs Market Value Analysis
This analysis compares OliX PharmaceuticalsInc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 17.41x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 93.21x to 17.41x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1387.16 | ₩129300.00 | x |
| 2017-12-31 | ₩1793.90 | ₩129300.00 | x |
| 2018-12-31 | ₩4223.45 | ₩129300.00 | x |
| 2019-12-31 | ₩3200.42 | ₩129300.00 | x |
| 2020-12-31 | ₩3344.07 | ₩129300.00 | x |
| 2021-12-31 | ₩1351.59 | ₩129300.00 | x |
| 2022-12-31 | ₩4809.65 | ₩129300.00 | x |
| 2023-12-31 | ₩3114.01 | ₩129300.00 | x |
| 2024-12-31 | ₩966.92 | ₩129300.00 | x |
| 2025-12-31 | ₩7426.34 | ₩129300.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently OliX PharmaceuticalsInc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -10.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -107.33%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.31x
- Recent ROE (-10.54%) is above the historical average (-61.47%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -29.11% | -932.79% | 0.03x | 1.21x | ₩-4.91 Billion |
| 2017 | -27.65% | -2116.65% | 0.01x | 1.16x | ₩-7.03 Billion |
| 2018 | -14.09% | -2563.58% | 0.01x | 1.01x | ₩-13.24 Billion |
| 2019 | -34.34% | -1269.79% | 0.03x | 1.08x | ₩-18.53 Billion |
| 2020 | -42.81% | -783.44% | 0.03x | 1.74x | ₩-23.91 Billion |
| 2021 | -160.44% | -808.70% | 0.04x | 4.68x | ₩-31.57 Billion |
| 2022 | -29.58% | -209.17% | 0.07x | 2.01x | ₩-26.09 Billion |
| 2023 | -38.31% | -111.94% | 0.17x | 2.06x | ₩-24.09 Billion |
| 2024 | -227.79% | -716.18% | 0.08x | 3.99x | ₩-42.44 Billion |
| 2025 | -10.54% | -107.33% | 0.08x | 1.31x | ₩-30.68 Billion |
Industry Comparison
This section compares OliX PharmaceuticalsInc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $328,962,346,017
- Average return on equity (ROE) among peers: -14.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| OliX PharmaceuticalsInc (226950) | ₩150.08 Billion | -29.11% | 0.30x | $1.76 Billion |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $76.42 Million |
| Green Cross (005250) | $1.45 Trillion | 1.27% | 0.81x | $355.67 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $3.44 Million |
| Pharmicell (005690) | $55.99 Billion | -70.00% | 0.14x | $594.51 Million |
| GeneOne Life Science Inc (011000) | $111.49 Billion | -69.75% | 0.35x | $54.38 Million |
| HLB Co. Ltd (028300) | $19.44 Billion | 0.00% | 0.66x | $4.30 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $16.56 Million |
| Seoulin Bioscience Co.Ltd (038070) | $83.06 Billion | -0.14% | 0.37x | $30.57 Million |
| Hyundai Bioscience Co. Ltd (048410) | $22.49 Billion | -13.82% | 0.46x | $622.85 Million |
| iNtRON Biotechnology Inc (048530) | $11.93 Billion | -9.93% | 0.65x | $57.85 Million |
About OliX PharmaceuticalsInc
OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepati… Read more